Literature DB >> 16046308

Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.

Abbas E Kitabchi1, Marinella Temprosa, William C Knowler, Steven E Kahn, Sarah E Fowler, Steven M Haffner, Reuben Andres, Christopher Saudek, Sharon L Edelstein, Richard Arakaki, Mary Beth Murphy, Harry Shamoon.   

Abstract

Insulin resistance and beta-cell dysfunction, two factors central to the pathogenesis of type 2 diabetes, were studied in relation to the development of diabetes in a group of participants with impaired glucose tolerance in the Diabetes Prevention Program (DPP) at baseline and after specific interventions designed to prevent diabetes. Participants were randomly assigned to placebo (n = 1,082), metformin (850 mg twice a day) (n = 1,073), or intensive lifestyle intervention (n = 1,079). The diabetes hazard rate was negatively associated with baseline insulin sensitivity (hazard rate ratio = 0.62-0.94 per SD difference, depending on treatment group and measure of sensitivity) and with baseline insulin secretion (hazard rate ratio = 0.57-0.76 per SD). Improvements in insulin secretion and insulin sensitivity were associated with lower hazard rates in all treatment arms (hazard rate ratio = 0.46-0.95 per SD increase and 0.29-0.79 per SD increase, respectively). In multivariate models that included the three metabolic variables (changes in body weight, insulin sensitivity, and insulin secretion) each significantly and independently predicted progression to diabetes when adjusted for the other two variables. The intensive lifestyle intervention, which elicited the greatest reduction in diabetes incidence, produced the greatest improvement in insulin sensitivity and the best preservation of beta-cell function after 1 year, whereas the placebo group, which had the highest diabetes incidence, had no significant change in insulin sensitivity and beta-cell function after 1 year. In the metformin group, diabetes risk, insulin sensitivity, and beta-cell function at 1 year were intermediate between those in the intensive lifestyle and placebo groups. In conclusion, higher insulin secretion and sensitivity at baseline and improvements in response to treatment were associated with lower diabetes risk in the DPP. The better preventive effectiveness of intensive lifestyle may be due to improved insulin sensitivity concomitant with preservation of beta-cell function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16046308      PMCID: PMC1360738          DOI: 10.2337/diabetes.54.8.2404

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  39 in total

1.  The natural history of impaired glucose tolerance in the Pima Indians.

Authors:  M F Saad; W C Knowler; D J Pettitt; R G Nelson; D M Mott; P H Bennett
Journal:  N Engl J Med       Date:  1988-12-08       Impact factor: 91.245

Review 2.  Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

Authors:  R A DeFronzo
Journal:  Diabetes       Date:  1988-06       Impact factor: 9.461

3.  Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body-fat distribution.

Authors:  S M Haffner; M P Stern; B D Mitchell; H P Hazuda; J K Patterson
Journal:  Diabetes       Date:  1990-03       Impact factor: 9.461

4.  The Whitehall Study: ten year follow-up report on men with impaired glucose tolerance with reference to worsening to diabetes and predictors of death.

Authors:  R J Jarrett; H Keen; P McCartney
Journal:  Diabet Med       Date:  1984-11       Impact factor: 4.359

5.  Association of elevated fasting C-peptide level and increased intra-abdominal fat distribution with development of NIDDM in Japanese-American men.

Authors:  R W Bergstrom; L L Newell-Morris; D L Leonetti; W P Shuman; P W Wahl; W Y Fujimoto
Journal:  Diabetes       Date:  1990-01       Impact factor: 9.461

6.  Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance.

Authors:  W K Ward; E C LaCava; T L Paquette; J C Beard; B J Wallum; D Porte
Journal:  Diabetologia       Date:  1987-09       Impact factor: 10.122

7.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

8.  Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913.

Authors:  L O Ohlson; B Larsson; P Björntorp; H Eriksson; K Svärdsudd; L Welin; G Tibblin; L Wilhelmsen
Journal:  Diabetologia       Date:  1988-11       Impact factor: 10.122

9.  Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians.

Authors:  S Lillioja; D M Mott; B V Howard; P H Bennett; H Yki-Järvinen; D Freymond; B L Nyomba; F Zurlo; B Swinburn; C Bogardus
Journal:  N Engl J Med       Date:  1988-05-12       Impact factor: 91.245

10.  Diabetes incidence in Pima indians: contributions of obesity and parental diabetes.

Authors:  W C Knowler; D J Pettitt; P J Savage; P H Bennett
Journal:  Am J Epidemiol       Date:  1981-02       Impact factor: 4.897

View more
  181 in total

Review 1.  Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.

Authors:  Vanita R Aroda; William C Knowler; Jill P Crandall; Leigh Perreault; Sharon L Edelstein; Susan L Jeffries; Mark E Molitch; Xavier Pi-Sunyer; Christine Darwin; Brandy M Heckman-Stoddard; Marinella Temprosa; Steven E Kahn; David M Nathan
Journal:  Diabetologia       Date:  2017-08-02       Impact factor: 10.122

Review 2.  Treatment of prediabetes.

Authors:  Mustafa Kanat; Ralph A DeFronzo; Muhammad A Abdul-Ghani
Journal:  World J Diabetes       Date:  2015-09-25

Review 3.  Diabetes prevention: can insulin secretagogues do the job?

Authors:  Barbara Westerhaus; Aidar R Gosmanov; Guillermo E Umpierrez
Journal:  Prim Care Diabetes       Date:  2010-12-24       Impact factor: 2.459

Review 4.  Metformin effects revisited.

Authors:  P Andújar-Plata; X Pi-Sunyer; B Laferrère
Journal:  Diabetes Res Clin Pract       Date:  2011-10-14       Impact factor: 5.602

Review 5.  Effect of genotype on success of lifestyle intervention in subjects at risk for type 2 diabetes.

Authors:  Peter Weyrich; Norbert Stefan; Hans-Ulrich Häring; Markku Laakso; Andreas Fritsche
Journal:  J Mol Med (Berl)       Date:  2006-12-13       Impact factor: 4.599

Review 6.  Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction.

Authors:  Katsutaro Morino; Kitt Falk Petersen; Gerald I Shulman
Journal:  Diabetes       Date:  2006-12       Impact factor: 9.461

7.  An abnormal screening glucose challenge test in pregnancy predicts postpartum metabolic dysfunction, even when the antepartum oral glucose tolerance test is normal.

Authors:  Ravi Retnakaran; Ying Qi; Mathew Sermer; Philip W Connelly; Anthony J G Hanley; Bernard Zinman
Journal:  Clin Endocrinol (Oxf)       Date:  2008-10-21       Impact factor: 3.478

8.  The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes.

Authors:  Jill Crandall; David Schade; Yong Ma; Wilfred Y Fujimoto; Elizabeth Barrett-Connor; Sarah Fowler; Sam Dagogo-Jack; Reubin Andres
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2006-10       Impact factor: 6.053

9.  Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study.

Authors:  R A DeFronzo; M A Banerji; G A Bray; T A Buchanan; S Clement; R R Henry; A E Kitabchi; S Mudaliar; N Musi; R Ratner; P Reaven; D C Schwenke; F D Stentz; D Tripathy
Journal:  Diabetologia       Date:  2009-12-10       Impact factor: 10.122

Review 10.  Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective.

Authors:  José Alejandro Luchsinger
Journal:  Eur J Pharmacol       Date:  2008-03-04       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.